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Rhodococcus sp. can infect wounds and medical devices,
mainly in immunosuppressed patients.1,2 Infections of
the cerebrospinal fluid (CSF) by this microorganism are
very infrequent. Herein, we present a case of late-onset
ventriculo-peritoneal shunt infection in an immunosup-
pressed adult caused by non-equi Rhodococcus. To our
knowledge, this constitutes the first reported case with
these characteristics.
A 62-year-old male was admitted to hospital with a four-
day history of fever and chills. Three years before, he had
been diagnosed with glioblastoma multiforme, which was
excised. He was also treated with chemotherapy and radio-
therapy and, at the time of admission, he was taking temo-
zolomide. One year before admission, he developed
hydrocephalus and a ventriculo-peritoneal shunt was
inserted. During the past month, he had difficulty walking
and episodes of urinary incontinence. In the 12 hours before
admission, he took two doses of oral amoxicillin-clavulanate.
Physical examination was normal, except for fever (38.5 8C),
discrete neck stiffness and a plaque of cellulitis on the neck
that followed the course of the shunt. No erosions or wounds
at this level were noted. Routine hematological and chemical
blood components were normal, with the exception of mild
lymphopenia (970 lymphocytes/ml). A cranial CTscan did not
show any increase in the size of the ventricles. The CSF
contained 81 white blood cells/ml (of which 86% were lym-
phocytes and 14% neutrophils), 65 mg/dl protein and
68.4 mg/dl glucose. CSF Gram stain was negative. Empiric
treatment with vancomycin plus ceftazidime was initiated,
and the shunt was removed 24 hours later. CSF aerobic
culture yielded Gram-positive coccobacillar microorganisms
that showed a positive reaction to catalase, nitrates, a-
glucosidase and alkaline phosphatase, and a negative reac-
tion to cytochrome oxidase. Colonies did not ferment carbo-
hydrates and could not hydrolyze hippurate, esculin, urea or
gelatin. The commercial identification system API Coryne
(bioMe´rieux, France) obtained code number 311004 (Rhodo-
coccus sp.). These colonies showed the absence of factor equi
and the identification of non-equi Rhodococcus sp. was
established. The empiric treatment was then changed to
ceftriaxone 4 g/24 h, to which the Rhodococcus strain was
susceptible. Clinical progress was quickly satisfactory and the
patient was discharged without symptoms after 13 days of1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.06.043antibiotic treatment, with no need for a new shunt. He
continued to have no sign of infection and was again operated
on for his brain tumor eight months later.
Rhodococcus sp. are Gram-positive facultative intracel-
lular pathogens. Infections caused by these microorganisms
are usually associated with cellular immunity defects.1,2
Infections caused by Rhodococcus equi affect mainly the
lungs and are sometimes wound related. Non-equi Rhodo-
coccus infections are associated with accidental or surgical
wound infections3 and medical devices2,4. Rhodococcus sp.
infections of CSF derivation catheters are extremely rare.
Scotton et al.5 reported the case of a womanwithmeningitis
caused by R. equi associated with an external ventricular
catheter. She was cured by removal of the catheter and
therapy with levofloxacin. Boughton and Atkin6 described
the early infection of a ventriculo-peritoneal shunt in an
infant, only two days after surgery. To our knowledge, we
report the first case of late-onset CSF shunt infection by non-
equi Rhodococcus in an adult. The fact that, in our patient,
the device had been inserted one year before manifestation
of the infection points to an unnoticed wound or erosion of
the skin favoring cellulitis and progression to the shunt as the
most probable mechanism of infection. The radiotherapy
the patient had previously received might have favored a
skin infection.7 Moreover, he could be considered as having a
certain degree of immunosuppression as he was being trea-
ted with temozolomide and showed mild lymphopenia. Su
et al. reported a higher incidence of lymphopenia (mainly
CD4+ lymphopenia) and opportunistic infections in 97
patients with melanoma treated with temozolomide,
although the doses used were at least 50% higher than those
normally employed for the treatment of glioblastoma.8
Ganie`re et al. reported the case of a man who was treated
with temozolomide for a glioblastoma and developed Pneu-
mocystis jirovecii pneumonia, brain abscess caused by Lis-
teria monocytogenes and Kaposi’s sarcoma. This patient,
however, was being simultaneously treated with a high dose
of glucocorticoids.9
Little is known about the antibiotic susceptibility of
non-equi Rhodococcus and antimicrobial therapy for
these infections should be selected according to suscept-
ibility testing.2 Our patient improved following treatment
with a third-generation cephalosporin and removal of the
shunt. Removal of the medical device is usually necessary
to cure shunt infections caused by usual bacterial patho-
gens.10,11 However, the previously published case of earlyPublished by Elsevier Ltd. All rights reserved.
e194 Letter to the Editorventriculo-peritoneal shunt infection in an infant caused
by Rhodococcus sp. had a satisfactory outcome with anti-
biotic treatment alone.6 In our patient, the shunt was
removed before microbiological diagnosis was made, so
it is uncertain whether his infection could have been cured
without shunt removal.
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